Ian B Jeffery1, Anubhav Das1, Eileen O'Herlihy1, Simone Coughlan1, Katryna Cisek1, Michael Moore2, Fintan Bradley3, Tom Carty3, Meenakshi Pradhan1, Chinmay Dwibedi1, Fergus Shanahan4, Paul W O'Toole5. 1. 4D pharma Cork Limited, Cavanagh Pharmacy Building, University College Cork, National University of Ireland, Cork, Ireland. 2. Department of Radiology, Cork University Hospital, Cork, Ireland. 3. Medical Physics Department, Cork University Hospital, Cork, Ireland. 4. 4D pharma Cork Limited, Cavanagh Pharmacy Building, University College Cork, National University of Ireland, Cork, Ireland; APC Microbiome Ireland, University College Cork, Ireland. 5. 4D pharma Cork Limited, Cavanagh Pharmacy Building, University College Cork, National University of Ireland, Cork, Ireland; APC Microbiome Ireland, University College Cork, Ireland; School of Microbiology, University College Cork, Ireland. Electronic address: pwotoole@ucc.ie.
Abstract
BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is a heterogeneous disorder, but diagnoses and determination of subtypes are made based on symptoms. We profiled the fecal microbiomes of patients with and without IBS to identify biomarkers of this disorder. METHODS: We collected fecal and urine samples from 80 patients with IBS (Rome IV criteria; 16-70 years old) and 65 matched individuals without IBS (control individuals), along with anthropometric, medical, and dietary information. Shotgun and 16S ribosomal RNA amplicon sequencing were performed on feces, whereas urine and fecal metabolites were analyzed by gas chromatography and liquid chromatography-mass spectrometry. Co-occurrence networks were generated based on significant Spearman correlations between data. Bile acid malabsorption (BAM) was identified in patients with diarrhea by retention of radiolabeled selenium-75 homocholic acid taurine. RESULTS: Patients with IBS had significant differences in network connections between diet and fecal microbiomes compared with control individuals; these were accompanied by differences in fecal metabolomes. We did not find significant differences in fecal microbiota composition among patients with different IBS symptom subtypes. Fecal metabolome profiles could discriminate patients with IBS from control individuals. Urine metabolomes also differed significantly between patients with IBS and control individuals, but most discriminatory metabolites were related to diet or medications. Fecal metabolomes, but not microbiomes, could distinguish patients with IBS with vs those without BAM. CONCLUSIONS: Despite the heterogeneity of IBS, patients have significant differences in urine and fecal metabolomes and fecal microbiome vs control individuals, independent of symptom-based subtypes of IBS. Fecal metabolome analysis can be used to distinguish patients with IBS with vs those without BAM. These findings might be used for developing microbe-based treatments for these disorders.
BACKGROUND & AIMS:Irritable bowel syndrome (IBS) is a heterogeneous disorder, but diagnoses and determination of subtypes are made based on symptoms. We profiled the fecal microbiomes of patients with and without IBS to identify biomarkers of this disorder. METHODS: We collected fecal and urine samples from 80 patients with IBS (Rome IV criteria; 16-70 years old) and 65 matched individuals without IBS (control individuals), along with anthropometric, medical, and dietary information. Shotgun and 16S ribosomal RNA amplicon sequencing were performed on feces, whereas urine and fecal metabolites were analyzed by gas chromatography and liquid chromatography-mass spectrometry. Co-occurrence networks were generated based on significant Spearman correlations between data. Bile acid malabsorption (BAM) was identified in patients with diarrhea by retention of radiolabeled selenium-75 homocholic acid taurine. RESULTS:Patients with IBS had significant differences in network connections between diet and fecal microbiomes compared with control individuals; these were accompanied by differences in fecal metabolomes. We did not find significant differences in fecal microbiota composition among patients with different IBS symptom subtypes. Fecal metabolome profiles could discriminate patients with IBS from control individuals. Urine metabolomes also differed significantly between patients with IBS and control individuals, but most discriminatory metabolites were related to diet or medications. Fecal metabolomes, but not microbiomes, could distinguish patients with IBS with vs those without BAM. CONCLUSIONS: Despite the heterogeneity of IBS, patients have significant differences in urine and fecal metabolomes and fecal microbiome vs control individuals, independent of symptom-based subtypes of IBS. Fecal metabolome analysis can be used to distinguish patients with IBS with vs those without BAM. These findings might be used for developing microbe-based treatments for these disorders.
Authors: Stephen J Keely; Andreacarola Urso; Alexandr V Ilyaskin; Christoph Korbmacher; Nigel W Bunnett; Daniel P Poole; Simona E Carbone Journal: Am J Physiol Gastrointest Liver Physiol Date: 2021-11-10 Impact factor: 4.052
Authors: Taojun Wang; Iris Rijnaarts; Gerben D A Hermes; Nicole M de Roos; Ben J M Witteman; Nicole J W de Wit; Coen Govers; Hauke Smidt; Erwin G Zoetendal Journal: Dig Dis Sci Date: 2022-05-27 Impact factor: 3.487
Authors: Dale A Fritsch; Matthew I Jackson; Susan M Wernimont; Geoffrey K Feld; Jennifer M MacLeay; John J Brejda; Chun-Yen Cochrane; Kathy L Gross Journal: BMC Vet Res Date: 2022-06-24 Impact factor: 2.792
Authors: Kendra J Kamp; Kevin C Cain; Angelita Utleg; Robert L Burr; Daniel Raftery; Ruth Ann Luna; Robert J Shulman; Margaret M Heitkemper Journal: Biol Res Nurs Date: 2020-07-15 Impact factor: 2.522
Authors: Laura A Bolte; Arnau Vich Vila; Floris Imhann; Valerie Collij; Ranko Gacesa; Vera Peters; Cisca Wijmenga; Alexander Kurilshikov; Marjo J E Campmans-Kuijpers; Jingyuan Fu; Gerard Dijkstra; Alexandra Zhernakova; Rinse K Weersma Journal: Gut Date: 2021-04-02 Impact factor: 23.059